Developing targeted therapies for patients living with rare and aggressive diseases

Ayala Pharmaceuticals develops precision medicines that target rare genetically driven cancers. The company targets the Notch pathway, a conserved signaling pathway involved in cell proliferation, differentiation, and survival – one that plays a key role in cancer progression across multiple types of cancer.

Ayala uses companion diagnostics to specifically treat patients with Notch mutations. Ayala has clinical programs in adenoid cyctic carcinoma (ACC) and desmoid (>$1B market). The Company recently announced promising results in tumor reduction from the Phase 3 desmoid trial.


Investing partner / fund: